Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial.

@article{Keller2001EfficacyOP,
  title={Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial.},
  author={Martin B. Keller and Neal D. Ryan and Michael Strober and Rachel Gittelman Klein and Stan Kutcher and Boris Birmaher and O. R. Hagino and Harold S. Koplewicz and Gabrielle A. Carlson and Gregory Clarke and Graham J. Emslie and D Feinberg and Barbara Geller and Vivek Kusumakar and George Makrydimas Stefania Papatheodorou and William H. Sack and Melissa Sweeney and Karen Dineen Wagner and Elizabeth B. Weller and Nancy C. Winters and Rosemary Oakes and James P. Mccafferty},
  journal={Journal of the American Academy of Child and Adolescent Psychiatry},
  year={2001},
  volume={40 7},
  pages={
          762-72
        }
}
  • M. Keller, N. Ryan, +19 authors J. Mccafferty
  • Published 2001
  • Psychology, Medicine
  • Journal of the American Academy of Child and Adolescent Psychiatry
OBJECTIVE To compare paroxetine with placebo and imipramine with placebo for the treatment of adolescent depression. METHOD After a 7- to 14-day screening period, 275 adolescents with major depression began 8 weeks of double-blind paroxetine (20-40 mg), imipramine (gradual upward titration to 200-300 mg), or placebo. The two primary outcome measures were endpoint response (Hamilton Rating Scale for Depression [HAM-D] score < or = 8 or > or = 50% reduction in baseline HAM-D) and change from… Expand
Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, multicenter, double-blind, placebo-controlled trial.
TLDR
Paroxetine was not shown to be more efficacious than placebo for treating pediatric major depressive disorder. Expand
An international, multicenter, placebo-controlled trial of paroxetine in adolescents with major depressive disorder.
TLDR
Results differed by age, with patients older than 16 years demonstrating a greater response to active treatment than younger adolescents, and paroxetine at 20-40 mg/day administered over a period of up to 12 weeks was generally well tolerated. Expand
Paroxetine in the treatment of adolescent major depression.
TLDR
This multicenter, 8-week, double-blind, placebo-controlled trial found paroxetine to be superior to placebo in the endpoint Hamilton Rating Scale for Depression (HAMD) score ≤8 (one of the two primary outcome measures), HAMD and Schedule for Affective Disorders and Schizophrenia for Adolescents-Lifetime version depressed mood items, and the Clinical Global Improvement score of 1 and 2. Expand
Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial.
TLDR
Fluoxetine 20 mg daily appears to be well tolerated and effective for acute treatment of MDD in child and adolescent outpatients. Expand
A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents.
TLDR
Treatment with citalopram reduced depressive symptoms to a significantly greater extent than placebo treatment and was well tolerated in this population of children and adolescents. Expand
Mirtazapine in the Treatment of Adolescents with Major Depression: An Open-Label, Multicenter Pilot Study
This multicenter, open-label study with a duration of 85 days was performed to evaluate the antidepressant efficacy and safety of mirtazapine (dose range, 30-45 mg) in 12-18-year-old adolescentsExpand
Paroxetine versus clomipramine in adolescents with severe major depression: a double-blind, randomized, multicenter trial.
TLDR
Paroxetine and clomipramine exhibit similar efficacy in adolescent depression, and these data support the serotonin hypothesis but do not confirm it in the absence of a placebo arm. Expand
Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS).
TLDR
The combination of FLX and CBT was superior to both monotherapy and PBO in terms of remission rates, but overall rates of remission remain low and residual symptoms are common at the end of 12 weeks of treatment. Expand
A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression.
TLDR
The data suggest that escitalopram may have beneficial effects in adolescent patients, and the drug appeared to be well tolerated. Expand
Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence
TLDR
The reanalysis of Study 329 illustrates the necessity of making primary trial data and protocols available to increase the rigour of the evidence base and access to primary data from trials has important implications for both clinical practice and research. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 80 REFERENCES
Response to desipramine treatment in adolescent depression: a fixed-dose, placebo-controlled trial.
TLDR
The routine use of short-term tricyclic antidepressant DMI in the treatment of adolescent depression is not supported by the data on hand and further investigations into what constitutes optimal psychopharmacological treatment of adolescents are warranted. Expand
A randomized, controlled trial of amitriptyline in the acute treatment of adolescent major depression.
TLDR
No definitive recommendation can be made regarding the efficacy of tricyclic antidepressants in the treatment of adolescent MDD. Expand
A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression.
TLDR
Fluoxetine was superior to placebo in the acute phase treatment of major depressive disorder in child and adolescent outpatients with severe, persistent depression, and complete remission of symptoms was rare. Expand
Adolescent depression: Controlled desipramine treatment and atypical features
TLDR
A relatively high rate of atypical depression was observed, suggesting the need for very large samples to detect differential treatment efficacy, should it exist in adolescents with major depression, and may have relevance to future investigation of therapeutic interventions in adolescent MDD. Expand
Multicenter open-label sertraline study in adolescent outpatients with major depression.
TLDR
In open treatment of adolescent MDD with sertraline, significant improvement occurred early on and was maintained for 22 weeks, and Absolute response rates varied depending on the rating scales used, definition of response, and length of treatment. Expand
Paroxetine in depressed adolescents with intellectual disability: an open label study.
TLDR
This preliminary, uncontrolled study of a few cases suggests that adolescents with intellectual disability and MDD may respond to paroxetine, and that adverse side-effects are mild. Expand
An open study of the effects of sertraline on adolescent major depression.
TLDR
It is suggested that sertraline might be useful in treating adolescents with major depression, and measures of depression were found to improve significantly, including suicidal ideation and most of the DSM-III-R symptoms of major depression. Expand
The pharmacotherapy of depressive illness in adolescents: an open-label comparison of fluoxetine with imipramine-treated historical controls.
TLDR
The findings add to recent evidence suggesting more favorable response to selective serotonin reuptake inhibitors than tricyclics in adolescents with depressive illness. Expand
Randomized, controlled trial of amitriptyline versus placebo for adolescents with "treatment-resistant" major depression.
TLDR
Although both treatment groups showed substantial response, at the end of treatment a substantial proportion of patients still had MDD of subsyndromal symptoms of depression, and this and other studies of tricyclic antidepressants question the use of this medication as first-line treatment for youths with MDD. Expand
Efficacy of desipramine in depressed outpatients. Response according to research diagnosis criteria diagnoses and severity of illness.
TLDR
Patients with intermittent depressive disorder improved significantly less frequently with desipramine than patients with major depressive disorder, and patients with lower pretreatment HAM-D scores did not. Expand
...
1
2
3
4
5
...